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Abstract
Background: Dysregulation of the epigenome is a common event in malignancy; however, deciphering the earliest
cancer-associated epigenetic events remains a challenge. Cancer epigenome studies to date have primarily utilised
cancer cell lines or clinical samples, where it is difficult to identify the initial epigenetic lesions from those that occur
over time. Here, we analysed the epigenome of human mammary epithelial cells (HMEC) and a matched variant cell
population (vHMEC) that have spontaneously escaped senescence and undergone partial carcinogenic transformation.
Using this model of basal-like breast carcinogenesis, we provide striking new insights into the very first epigenetic
changes that occur during the initial stages of malignancy.
Results: The first phase of malignancy is defined by coordinated changes in the epigenome. At the chromatin level, this
is embodied in long-range epigenetic deregulation, which involves the concomitant but atypical acquisition or loss of
active and repressive histone modifications across large regional blocks. Changes in DNA methylation also occurs in a
highly coordinated manner. We identified differentially methylated regions (DMRs) in the very earliest passages of
vHMECs. Notably, we find that differential methylation targets loci regulated by key transcription factors including p53,
AHR and E2F family members suggesting that epigenetic deregulation of transcription factor binding is a key event in
breast carcinogenesis. Interestingly, DMRs identified in vHMEC are extensively methylated in breast cancer, with
hypermethylation frequently encroaching into neighbouring regions. A subset of vHMEC DMRs exhibited a strong
basal-like cancer specific hypermethylation.
Conclusions: Here, we generated epigenome-wide maps of the earliest phase of breast malignancy and show
long-range epigenetic deregulation and coordinated DNA hypermethylation targets loci regulated by key transcription
factors. These findings support a model where induction of breast cancer occurs through epigenetic disruption of
transcription factor binding leading to deregulation of cancer-associated transcriptional networks. With their stability
and very early occurrence, vHMECs hypermethylated loci could serve as excellent biomarkers for the initial detection
of basal breast cancer.
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Background
The epigenetic control of gene expression plays a critical
role in the development of normal cells and is exten-
sively deregulated in all cancers, including breast cancer
(reviewed in Baylin and Jones [1]). Hypermethylation
frequently occurs in high-density clusters termed CpG
islands and is often associated with gene promoters and
transcriptional repression in cancer, whereas decreased
methylation at regulatory elements is associated with
gene activation [1,2]. Alterations in DNA methylation
contribute to carcinogenesis via a variety of mechanisms
including the silencing of tumour suppressors [1,2] and
reactivation of transposons [3], genomic instability [4,5]
and blocking differentiation [6]. Furthermore, the cancer
DNA methylation profile can be associated with specific
molecular subtypes [7-9], various clinicopathological
parameters (reviewed in Locke and Clark [10]) and
response to endocrine therapy [11,12].
While epigenetic dysregulation in cancer is well estab-
lished, the timing and extent of epigenetic change during
carcinogenesis remains largely unknown. Most studies
utilise comparisons of cancer cell lines or cancer tissue
samples with normal tissue to identify cancer-associated
epigenetic aberrations that occur during tumour devel-
opment. However, these studies cannot identify the early
events associated with epigenetic remodelling during
transformation. To address this issue, we utilised the hu-
man mammary epithelial cell (HMEC) model system
[10,13]. HMECs are derived from normal breast tissue
removed from healthy women during breast reduction
mammoplasty [14]. In culture HMEC undergo two dis-
tinct phases of growth separated by a temporary period
of growth arrest similar to senescence, termed ‘selection’.
Cells from the two growth phases are termed HMEC
prior to selection and then, after overcoming senes-
cence barriers during selection, are termed variant
HMEC (vHMEC) during the second growth phase
[15,16]. When compared to HMECs, vHMECs exhibit
multiple cancer-associated gene expression and epigen-
etic changes and are considered to represent a partially
transformed pre-malignant breast cell (reviewed in
Locke and Clark [10] and Hinshelwood and Clark [13]).
Such changes include silencing of the p16ink4a tumour
suppressor associated with promoter hypermethylation
[15,17-19], silencing of the transforming growth factor
beta pathway via acquisition of repressive chromatin
[20] and increased expression of the cancer-associated
chromatin methyltransferase EZH2 [20]. Due to its
extended lifespan and multiple cancer-associated ex-
pression changes, the HMEC system provides a model
of partial carcinogenic transformation from normal to
pre-malignancy. Therefore, the HMEC system is an
ideal tool for the identification of the first epigenomic
events occurring during early breast carcinogenesis.
In order to understand the role of epigenomic deregu-
lation in breast carcinogenesis, we performed detailed
expression, DNA methylation and chromatin modifica-
tion profiling of a set of HMECs and isogenic vHMECs.
We show that epigenomic aberrations in key regulatory
pathways and across domains occur during the very
earliest stages of breast carcinogenesis. Furthermore,
comparison to The Cancer Genome Atlas BReast invasive
CArcinoma (TCGA-BRCA) cohort demonstrates that the
methylation aberrations we identified in vHMEC are com-
mon in basal-like breast tumours suggesting that epigen-
etic lesions occurring early in carcinogenesis are derived
by similar reprogramming events.
Results
vHMEC is a model of early basal-like breast
carcinogenesis
To gain a more detailed understanding of the early epi-
genetic changes that occur in the first stages of carcino-
genesis, we performed epigenome-wide profiling (gene
expression, DNA methylation and chromatin modifica-
tions [GEO:GSE58882]) of four isogenic HMEC/vHMEC
lines (Bre12, Bre38, Bre67 and Bre98). Given their basal
culture conditions [14], it is likely that vHMECs resem-
ble the basal-like molecular subtype of breast cancer. To
confirm this, we first classified the vHMEC lines into
the intrinsic molecular subtypes of breast cancer using
Affymetrix GeneChip expression data with the PAM50
classifier [21]. As highlighted by Sorlie and colleagues
[22], it is important that expression array data are gene-
centred in addition to standard normalisation procedures
prior to PAM50 classification. To ensure our findings
were reproducible, we performed the gene-centred ana-
lysis with two independent publicly available datasets
([GEO:GSE2034] [23] and [GEO:GSE3494] [24]). After
clustering, we found that the vHMEC lines from all four
donors classified into the basal-like breast cancer subtype
in both data sets, supporting the use of these cells as a
model to study breast cancer (Figure 1A [GEO:GSE2034]
and Additional file 1: Figure S1 [GEO:GSE3494]).
Next we aimed to identify the gene expression changes
that potentially drive the earliest steps in development of
breast cancer and/or basal breast cancer. First, we per-
formed multi-dimensional scaling (MDS) analysis on the
500 most variably expressed genes across all donors and
time points (Additional file 1: Figure S2A) which sepa-
rated HMEC and vHMEC into two distinct clusters on
dimension 1, indicating that selection (that is, the escape
from senescence) is the largest source of variation in our
dataset rather than inter-individual variation or extended
time in culture.
Subsequent limma analysis identified 2,121 and 1,972
genes differentially expressed in early and late vHMEC, re-
spectively, when compared to HMEC (adjusted P < 0.05,
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Figure 1B). Validation of differential expression was per-
formed on a subset of eight genes by quantitative poly-
merase chain reaction (qPCR) and exhibited high
correlation with array profiling (Additional file 1: Figure
S2B). The expression level of these approximately 2,000
differentially expressed genes was consistent across both
the early and late vHMEC time points (Figure 1C), further
indicating that the initial escape from senescence (selection)
is the greatest contributor to differential gene expression.
Given the high similarity between the vHMEC time points,
further expression analyses were performed on the early
vHMEC time point only.
Figure 1 Summary of gene expression changes in vHMEC. (A) Hierarchical clustering of the PAM50 expression profile of vHMEC and a breast
cancer cohort [GEO:GSE2034] classifies vHMEC (black box) into the basal-like molecular subtype of breast cancer. (B) The expression profile of
differentially expressed genes in HMEC (light blue) and early and late vHMEC (orange and red, respectively) clusters samples into separate HMEC
and vHMEC clusters. (C) The t-statistic of genes that gain (orange) or lose expression (red) in vHMEC is stable in early and late vHMEC indicating
the vHMEC expression pattern is stable even after extended time in culture.
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Deregulation of polycomb, MYC and the p53 pathway
drive early carcinogenesis
To understand the impact of gene expression change on
the biology of vHMEC and its ability to overcome senes-
cence, we performed Ingenuity Pathway Analysis (IPA).
IPA identified that genes differentially expressed in
vHMEC were significantly enriched for functions related to
cancer (P < < 0.001, Additional file 1: Figure S2C), includ-
ing cellular growth and proliferation, cellular movement,
cell cycle and, DNA replication, recombination and repair
(P < < 0.001). In addition, genes associated with develop-
ment were enriched, indicating a role for development-
related genes in the vHMEC’s escape from senescence.
The two most significant pathways identified by IPA
contained known breast oncogenes, specifically MYC
(Figure 2B) and the histone methyltransferase EZH2
(Figure 2B). IPA transcription factor (TF) analysis pre-
dicted activation of both MYC and EZH2 in vHMEC
Figure 2 Ingenuity pathway analysis (IPA) identifies deregulation of MYC and EZH2/polycomb in vHMEC. (A) The two most significant gene
expression pathways identified by IPA involve deregulation of the proto-oncogene MYC and (B) the epigenetic regulator and member of the
polycomb family, EZH2 (shading represents t statistic). (C) Gene set enrichment analysis demonstrates up-regulation of MYC targets and
(D) down-regulation of polycomb target genes in vHMEC in a pattern identical to that reported in cancer.
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(P = 1.33 × 10−13 and 2.12 × 10−03, respectively, Additional
file 2: Table S1). In addition to the identification of gene
expression pathways and enrichment of biological func-
tions, IPA can predict alterations in the apparent activity
of transcription factors (TF). IPA TF analysis predicted
activation of EZH2 and MYC, in agreement with their in-
creased expression levels, as well as several other cancer-
associated TFs. These included activation of the NF-κB
(including pathway members NFKB1 and RELA), and E2F
(including pathway members E2F1, E2F2 and E2F3) sig-
nalling pathways, activation of the stem cell/cancer-associ-
ated transcription factor NANOG and activation of the
ligand-activated transcription factor AHR. Inhibited TFs
included the tumour suppressing p53 and Rb pathways
(including pathway members RB1 and CDKN2A (p16)).
Western blot analysis of AHR in HMEC and vHMEC
was performed (Additional file 1: Figure S3A). When ac-
tive, AHR/ARNT form a complex, and this state was ob-
served in vHMEC and not in HMEC (Additional file 1:
Figure S3B). Intriguingly, ANRT was identified as inhibited
in vHMEC by IPA, and the AHR/ARNT target genes
CYP1A1 and CYP1B1 [25] are both down regulated at the
mRNA level relative to HMEC (adjusted P = 0.03 and
0.000057, respectively). The predicted inhibition of ARNT
and the apparent silencing of xenobiotic metabolising
AHR target genes may suggest that activation of AHR in
vHMEC is in relation to its putative roles in development
or other novel processes rather than xenobiotic response.
The increased activity of MYC and a related pathway
identified by IPA (Figure 2A and Additional file 2: Table
S1) suggests a key role for activating MYC in the
capacity of vHMEC to overcome senescence barriers. To
investigate this further, we assessed the differential ex-
pression patterns of the MYC, PRC and CORE modules
published by Kim et al. [26]. Together, these gene sets
can distinguish the expression patterns of cancer cells
from that of stem cells and are comprised of genes acti-
vated by MYC (MYC_MODULE) and genes silenced by
PRC2 (PRC_MODULE) in cancer and stem cells and a
set of genes activated in stem cells only by a core group of
pluripotency factors (CORE_MODULE). In vHMEC, we
observed enrichment of up- and down-regulated genes in
the MYC and PRC modules, respectively (Figure 2C, D,
respectively, family-wise error rate P value <0.05) and no
significant change in the CORE module genes (P = 0.06,
Additional file 1: Figure S2D), similar to the expression
pattern of cancer [26]. Furthermore, the deregulation of
the MYC and PRC modules matches the observed in-
crease in MYC and EZH2 expression and their predicted
increase in activity by IPA.
Tumour-suppressing miRNA are silenced in vHMEC
To assess the potential contribution of the deregulation
of microRNA (miRNA) expression in the capacity of
vHMEC to overcome senescence (and, therefore, in early
carcinogenesis), we profiled miRNA expression in a sub-
set of HMEC and early vHMEC (donors Bre12, Bre67
and Bre98) by Taqman® Low-Density Array (TLDA; Life
Technologies, Carlsbad, USA). TLDA analysis identified
four miRNA with a statistically significant (P < 0.05) loss
of expression (Figure 3A). Notably, of the four statisti-
cally significantly differentially expressed miRNA, three
fell into clusters (Figure 3B, C). Both hsa-mir-143 and
hsa-mir-145 are encoded by the same gene, which
Figure 3 Differentially expressed miRNA in the HMEC model system. (A) Expression profile of the four differentially expressed miRNA (hsa-mir-143,
hsa-mir-145 hsa-mir-519a and hsa-mir-199a), and hsa-mir-519a cluster associated miRNAs (hsa-mir-522 and hsa-mir-512) in vHMEC. hsa-mir-519a
clustered RNA exhibited a similar but not significant change in expression in vHMEC, indicating that this cluster may be regulated as a unit during
carcinogenesis. (B) The hsa-mir-143/145 cluster that exhibits simultaneous silencing in vHMEC. (C) The hsa-mir-519a cluster on chromosome 19q13.41
contains many other miRNA including two also assayed by the TLDA.
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accounts for their similar expression profile. Two copies
of hsa-mir-519a are located within a very large cluster of
miRNA on chromosome 19. Two other miRNA from the
hsa-mir-519a cluster were assayed by the TLDA platform
and exhibited a similar, although non-significant, change
in gene expression (hsa-mir-522 and hsa-mir-512,
Figure 3A) indicating that this cluster may be regulated as
a single unit.
Next, we identified which experimentally validated and
predicted target genes of the four vHMEC-silenced miRNA
in the TarBase and microrna.org databases [27,28] exhib-
ited increased expression in vHMEC. This identified 470
interactions (196 unique genes, Additional file 2: Table S2)
from the microrna.org database and six validated targets
from the TarBase database (Additional file 2: Table S3).
Notably, several key cancer-associated genes were in-
cluded in the list of deregulated targets, including MYC
(hsa-mir-145), EZH2 (hsa-mir199a) and members of
the p53 pathway (MDM2 and CDKN1A targeted by hsa-
mir-199a and; hsa-mir-519a and hsa-mir-145, respectively).
Additionally, hypergeometric testing using the MSigDB C2
Canonical Pathways database (Additional file 1: Figure S4)
revealed that cell cycle regulation, proliferation and p53
regulated pathways were enriched within the predicted
miRNA targets.
Long-range epigenetic regulation is an early cancer event
While the deregulation of individual oncogenes and
tumour suppressors is an important event in cancer, gene
expression changes can also affect large domains of the
genome containing multiple genes that exhibit a concord-
ant change in expression in a phenomenon termed long-
range epigenetic regulation (LRER) [29,30]. To study the
role of long-range epigenetic activation (LREA) and silen-
cing (LRES), we performed ChIP-chip analysis of H3K9ac
on Bre12 and Bre38 and, H3K27me3 on Bre12, Bre38,
Bre67 and Bre98 paired HMEC/vHMEC lines and com-
bined with the expression data to look for concordant
changes in chromatin-associated activation or repression.
Analysis identified 33 regions of LREA and 41 regions of
LRES based on change in expression, H3K9ac or
H3K27me3 (Additional file 2: Table S4). On average, LREA
regions were 0.5 Mb in length and contained an average of
nine genes (Figure 4A) and LRES regions were 1.1 Mb and
contained an average of eight genes (Figure 4B). Hypergeo-
metric testing revealed that genes within LREA regions
were enriched in gene sets associated with transcription
and maintenance of the DNA (Additional file 1: Figure
S5A), whereas LRES genes were enriched by gene sets as-
sociated with cancer and involved in the interaction with
the extracellular environment (Additional file 1: Figure
S5B). To investigate TF deregulation as a mechanism of
LRER region formation, we interrogated LRER regions for
TF binding sites (TFBS) associated with deregulated TF
identified by IPA. TFBS were identified using a set of
evolutionarily conserved, computationally derived TFBS
available from the UCSC genome browser website [31,32].
The majority of TFBS tested exhibited no enrichment in
Figure 4 Example LRER regions occurring in vHMEC. (A) LREA region LREA.exp_10 at chromosome 4q21.21 was identified by its expression
profile and contains four genes that exhibit concordant gain in expression, loss of H3K27me3 and gain in H3K9ac. (B) LRES region
LRES.K27me3_14 (identified by gain in H3K27me3) at chromosome 20p12.3 contains six genes and exhibits concordant loss of expression
and H3K9ac marking and gain in H3K27me3 marking.
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LRER. However, LRES regions were significantly depleted
for sites associated with AHR, ARNT, E2F family members
and MYC (Additional file 1: Figure S6).
DNA methylation changes occur early in carcinogenesis
The timing of DNA methylation changes during carcino-
genic transformation remains largely unknown. To investi-
gate the acquisition of differentially methylated regions
(DMRs) during the earliest phases of carcinogenesis, we
performed DNA methylation profiling using MBDCap-seq
(see ‘Methods’) on HMEC lines (Bre12, Bre38, Bre67 and
Bre98) and early and late passage vHMEC. Bioinformatic
analysis identified 813 and 286 regions of hyper- and
hypomethylation, respectively, in vHMEC (Figure 5A, B)
that were stably maintained between the early and late
vHMEC time points. Five gene-associated hypermethylated
loci were selected for validation by clonal bisulphite se-
quencing and all regions exhibited an increase in the
density of heterogeneous methylation between HMEC
and vHMEC (Additional file 1: Figure S7).
Next, we asked if DMRs observed in vHMEC were asso-
ciated with functional genomic features. Using RefSeq gene
annotations, hypermethylated DMRs were statistically sig-
nificantly (P < 0.05) enriched at CpG island loci and gene
promoters (Additional file 1: Figure S8). To identify poten-
tial functional non-genic regions, we performed ChIP-seq
Figure 5 Summary of DNA methylation profiling of the HMEC model system. (A) The DNA methylation profile of the 813 identified DMRs in
HMEC (light blue) and early and late vHMEC (orange and red, respectively). Loci hypermethylated in early vHMEC typically exhibit a similar profile
in the late vHMEC time point despite extended time in culture. (B) A further 286 regions exhibited stable hypomethylation in the vHMEC
samples. (C) ChIP-seq profiling was used to annotate the HMEC genome into eight categories based on the profile of H3K4me3, H3K27ac,
H3K36me3 and H3K27me3 including four classes of promoter, regions of predicted transcriptional activity, putative enhancers and polycomb
repressed loci. (D) Hypermethylated DMRs were frequently found at regions of predicted low activity such as Promoters 2 and 3, bivalent
promoters and polycomb repressed loci as well as putative enhancers. Hypomethylated DMRs predominately affected regions of predicted high
activity, such as promoters (Promoter_1) and putative enhancers.
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profiling of H3K4me3, H3K27ac, H3K36me3 and
H3K27me3 in Bre98 HMEC and vHMEC. Overlapping
ChIP-seq peaks were used to classify 63,526 regions in
HMEC and 61,096 in vHMEC into eight functional cat-
egories (designated Promoter_1, Promoter_2, Promoter_3,
Bivalent_Promoter, Enhancer, Transcribed_Enhancer,
Transcribed and Polycomb_Repressed, Figure 5C). Hyper-
methylated DMRs were enriched at low predicted activity
promoters (Promoter_2 and 3), putative enhancer loci and
polycomb regulated regions (Bivalent_promoter and Poly-
comb_Repressed). In contrast, hypomethylation was
enriched at high activity promoters (Promoter_1) and
heavily enriched (approximately 14-fold, P < 0.05) at the
Enhancer category (Figure 5D).
Next we tested the influence of promoter and TFBS
hypermethylation on the biology of vHMEC. A total of
272 hypermethylated DMRs were associated with the pro-
moters of 161 genes. We used these genes to perform
Gene Set Enrichment Analysis (GSEA) in the MSigDB C2
curated gene set database [33]. Promoter hypermethylated
genes in vHMEC were enriched in 48 gene sets that were
predominately associated with cancer, polycomb regula-
tion and p53 (n = 20, 11 and 3 for cancer, polycomb and
p53 associated gene sets, respectively, Additional file 1:
Figure S9A). Interestingly, several individual p53 and
polycomb-related genes were identified as deregulated at
the expression level by IPA, suggesting that p53 and poly-
comb deregulation involves multiple levels of genomic
control (that is, both the transcriptome and methylome).
At TFBS, hypermethylated DMRs were enriched for sev-
eral TFs, most notable of which were the ligand activated
and cancer-associated AHR, the development-associated
PAX5 and cell cycle/cancer-related E2F family members
(Additional file 1: Figure S9B). Overall, vHMEC DMRs
impacted an independent set of genes with similar func-
tions to those identified by gene expression analysis (that
is, p53, polycomb, E2F and AHR regulation).
vHMEC differentially methylated regions are detected in
breast cancer
Differential methylation that occurs very early during
transformation may provide useful biomarkers to detect
breast cancer. To determine if the early DMRs we identi-
fied in vHMECs were present in breast cancer, we analysed
Infinium HumanMethylation450 BeadChip® (HM450)
DNA methylation data obtained from TCGA-BRCA co-
hort (see ‘Metho7ds’). Given the basal-like phenotype of
vHMEC, we performed this analysis using all tumours and
then separately with just the basal-like subtype. The 813
hypermethylated vHMEC DMRs overlapped with 2,430
HM450 probes, of which 1,560 or 961 were hypermethy-
lated in all tumours or basal-like tumours, respectively
(adjusted P values <0.05, Additional file 1: Figure S10A).
This high frequency of hypermethylated probes in
vHMEC DMRs represents an approximately twofold en-
richment of hypermethylation over what is expected to
occur at random (P < 0.05). The enrichment of vHMEC
DMRs for TCGA-BRCA hypermethylation suggests that
these regions may be able to distinguish cancer from nor-
mal breast cells in both a general and basal-like specific
manner. Therefore, we performed a receiver operating
characteristic (ROC) analysis on TCGA_BRCA methyla-
tion to identify regions of potential diagnostic significance
across all breast cancer subtypes. From the 813 vHMEC
DMRs, 38 could sensitively and specifically separate tu-
mours from normal in the training cohort (Additional file 2:
Table S5). In the test cohort, all 38 regions exhibited an
area under the curve (AUC) of >0.91, indicating the ana-
lysis is robust. Further validation was performed for a sub-
set of ten loci that also overlapped probes from the
Infinium HumanMethylation27 BeadChip® (HM27)
DNA methylation platform. In the HM27 cohort, these
regions exhibited an AUC of between 0.76 and 0.98
(Additional file 2: Table S5), confirming their diagnostic
capacity in an independent dataset. Examples of diag-
nostic DMRs, associated with LCT4S (promoter),
COX7A1 (promoter), TRIM62 (intronic) and EPHB3
(promoter), are shown in Figure 6 and Additional file 1:
Figure S11.
Given the early nature of methylation changes in
vHMEC, it is possible that regions of hypermethylation
are more extensive in cancer due to ‘spread’ of aberrant
DNA methylation. Two candidate diagnostic vHMEC
DMRS, associated with the genes LCT4S and EPHB3, ex-
hibited a high AUC despite only overlapping two and
three HM450 probes, respectively. In TCGA-BRCA co-
hort, several probes immediately adjacent to these regions
also exhibited hypermethylation in cancer when compared
to normal (Figure 6C and Additional file 1: Figure S11C)
and could therefore improve the cancer specificity of these
loci. With these additional probes included, ROC analysis
revealed an increased AUC for both genes (Figure 6D
AUC = 0.99 and Additional file 1: Figure S11D AUC=
0.99), supporting the possibility of methylation ‘spread’ in
cancer. We also asked if DMRs were associated with al-
tered gene expression in the same TCGA breast cancer
samples. The correlation between methylation and ex-
pression was variable for each of the genes (R2 ≤ 0.11,
0.3, 0.23 and 0.6 for LTC4S, TRIM62, EPHB3 and
COX7A1, respectively); however, all diagnostic loci
overlapped with the region where the correlation be-
tween methylation and expression was highest (Add-
itional file 1: Figure S12), indicating that methylation
at these loci may impact gene expression. Additionally,
the DMRs in EPHB3 and TRIM62 overlapped with the
binding sites of transcription factors identified as
deregulated by IPA (Additional file 2: Table S6). Not-
ably, the EPHB3 methylated region, contained p53,
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E2F and AHR sites and the TRIM62 methylated region
contained p53 and PAX5 sites, suggesting that these
specific loci may be important in epigenetic deregula-
tion of these genes.
In addition to general cancer diagnosis, vHMEC DMRs
may be useful in separating basal-like tumours from the
other subtypes. To this end, we repeated the ROC analysis
of vHMEC DMRs to determine if any could separate
basal-like tumours from all other tumour subtypes. Given
the lower levels of methylation in basal-like tumours
when compared to other subtypes (Additional file 1:
Figure S10A), to reduce the identification of hypo-
methylated regions, we only analysed vHMEC DMRs
that overlapped one or more HM450 probe that was
hypermethylated in basal-like tumours (313 vHMEC
DMRs overlapping 1,750 HM450 probes). Using an AUC
cut off of >0.7, 14 candidate loci could separate basal-like
from other tumours (Additional file 2: Table S7) although
only four exhibited hypermethylation in basal-like when
compared to other subtypes. For the four basal-like hyper-
methylated regions, two were associated with FOXA1
(vHMEC DMRs chr14-3118 and chr14-14790), one with
LZTS1 (chr8-12256) and one within CIRBP (chr19-
47460). We again inspected the regions for spread of
hypermethylation into probes adjacent to the vHMEC
DMR, and for the FOXA1 and LZTS1 regions, multiple
adjacent probes did exhibit hypermethylation (Figure 7
and Additional file 1: Figure S13A, respectively) whereas
CIRBP did not (Additional file 1: Figure S13B). FOXA1 ex-
hibited the most widespread methylation in basal-like
Figure 6 The methylation profile of vHMEC hypermethylated loci can identify tumour from normal in the TCGA breast cancer cohort. (A) HM450
probes overlapping with vHMEC DMR chr19-37205 are hypermethylated in tumours in the TCGA-BRCA cohort. (B) DMR chr19-37205 overlaps the
COX7A1 promoter associated CpG island. Methylation at the locus was able to separate tumour from normal tissue in the TCGA-BRCA cohort (AUC > 0.94).
(C) vHMEC DMR chr5-12238 overlapped two HM450 probes; however, in the TCGA-BRCA cohort, several adjacent probes also exhibited increased
methylation. (D) Hypermethylation of DMR chr5-12238 overlapping and adjacent probes (covering the LCT4S promoter) was specific to tumours in the
TCGA-BRCA cohort (ROC analysis AUC> 0.97). Additionally, a small independent cohort of HM27 profiled samples also exhibited tumour-specific
methylation at this locus (AUC= 0.94).
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tumours, with hypermethylation encompassing two separ-
ate regions; a very large region covering much of the
FOXA1 gene body and ending approximately 6 kb down-
stream of the transcription termination site (region A)
and a shorter region approximately 2 kb upstream of the
transcription start site (region B). ROC analysis revealed
an AUC of 0.98 and 0.84 in the training and testing
cohorts, respectively, for region A and 0.93 and 0.84 for
region B (Figure 7). Similarly for LZTS1 (Additional file 1:
Figure S13A), with adjacent probes included, methylation
was highly specific to basal-like tumours with AUC of
0.95 and 0.86 in the training and test cohorts, respectively.
Hypermethylation of the LZTS1 transcription start site
did not exhibit an association with expression in TCGA
breast tumours; however, FOXA1 (R2 ≤ 0.75 and 0.67 for
regions A and B, respectively) and CIRBP (R2 ≤ 0.212)
both exhibited loss of expression with increased methyla-
tion (Additional file 1: Figure S14). Additionally, the
FOXA1 region A and CIRBP regions contained binding
sites for p53 and AHR and, p53 and PAX5, respectively,
all of which have been identified as deregulated in prior
analyses (Additional file 2: Table S6).
Discussion
The progression from a normal cell to a cancer cell in-
volves genome-wide epigenetic deregulation and altered
gene expression; however, the initial epigenetic lesions
that occur during early carcinogenesis remain largely un-
known. Here we utilised a model that recapitulates pre-
malignant phase of basal-like breast carcinogenesis [34]
and found significant alterations in DNA methylation
and chromatin modification patterns that were associ-
ated with dysregulation of cancer-associated genes and
pathways; specifically, genes and loci targeted by, EZH2/
polycomb, MYC, AHR and the p53 pathway. Notably,
these patterns of epigenetic deregulation were stable
over an extended period of cell culture and occurred
similarly in four independent HMEC lines, suggesting an
orchestrated process of alteration in DNA methylation
and chromatin modification.
Figure 7 The FOXA1 locus is specifically methylated in basal-like tumours in the TCGA HM450 cohort. Two regions (regions A and B) containing
four vHMEC DMRs that flank (but not cover) the FOXA1 promoter exhibit increased methylation specific to basal-like tumours (region A AUC > 0.84 and
region B AUC > 0.84).
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The hypermethylation of key transcription factor bind-
ing sites occurs in vHMECs and may indicate a putative
mechanism to establish genome-wide differential methy-
lation in cancer. For example, activation of AHR may
lead to a coordinated change in the epigenetic landscape
by triggering the hypermethylation of its binding sites.
AHR is a ligand activated transcription factor that has
previously been implicated as having roles in differenti-
ation and cancer [35-40] and we show that AHR is
active in vHMEC. In MCF7 cells, AHR activation has
been linked to the silencing of BRCA1 by recruitment of
DNA methyltransferases to the BRCA1 promoter region
[41-43]. Additionally, in keratinocytes AHR is reported
to induce the silencing and hypermethylation of the
CDKN2A (p16) tumour suppressor gene and the inhib-
ition of p53 signalling [44]. Notably, the silencing of p16
and subsequent promoter hypermethylation is an essential
component of the process of generating vHMEC [15,18].
Together, these findings may suggest that activation of
AHR could contribute to the extensive epigenomic change
observed in vHMEC (including hypermethylation of
CDKN2A), with potentially far ranging effects on the biol-
ogy of carcinogenesis, such as the inhibition of p53 in
vHMEC [44]. The observed inhibition of p53 signalling in
vHMEC is intriguing, given that vHMEC are reported to
express high levels of wild type p53 protein [45]. However,
instead of modulation or alteration of the p53 protein/gene,
we observed DNA hypermethylation of its target genes and
loci. Additionally, we identified loss of expression of the
p53-interacting/tumour-suppressing miRNA mir143/145
cluster. The mir143/145 cluster silenced in vHMEC is re-
ported to act downstream of p53 by promoting cell death
[46], further suggesting that p53 activity is impeded via
silencing of its targets and inhibition of downstream signal-
ling. Similar to p53, the PAX5 transcription factor also
exhibited frequent hypermethylation of its target sites in
vHMEC. Interestingly, PAX5 itself is reported as being fre-
quently methylated in breast cancer [47,48] and its overex-
pression in cell lines is reported to reduce the cancer
phenotype by promoting normal epithelial characteristics
[49]. In vHMEC, PAX5 remains unmethylated, suggesting
it is the disruption of PAX5 targets rather than of the regu-
lator itself that may facilitate carcinogenesis.
Interestingly, DMRs identified in vHMEC were exten-
sively methylated in breast cancer, with hypermethylation
frequently found to have extended into neighbouring re-
gions. With their stability and very early occurrence,
vHMEC hypermethylated loci could therefore serve as ex-
cellent biomarkers for the initial detection of cancer. In-
deed, we found that a subset of the vHMEC DMRs exhibit
a strong cancer-specific DNA methylation signature and
additionally we determined a set of loci that could specif-
ically identify basal-like tumours. Primarily, these loci
were frequently associated with genes that have known
roles in cancer, for example, FOXA1, LZTS1 and CIRBP.
Increased methylation at two regions surrounding FOXA1
also exhibited a strong correlation with decreased expres-
sion. Notably hypermethylation of these two regions has
previously been reported in leukaemia [50], colorectal
cancer [51] and pancreatic cancer [52], indicating that
they are potential regulatory loci for FOXA1. Given that
basal-like cancers and HMEC express low levels of
FOXA1, hypermethylation at these regions may play a role
in reducing the transcriptional plasticity of the FOXA1
locus. Interestingly, several candidate biomarker loci also
overlapped with predicted binding sites of the p53, AHR
and PAX5 transcription factors, further indicating a key
role for hypermethylation at these transcription factor
binding sites during carcinogenesis.
Conclusions
The HMEC model system provides an excellent tool to
study the biology of early breast carcinogenesis with the
potential to deliver clinically relevant biomarkers for the
detection and classification of breast cancer. Addition-
ally, our results indicate that the initial cancer driving
events involve genome-wide epigenetic silencing of tran-
scription factor targets that potentially disrupt gene
networks. Finally, we show that in pre-malignancy dys-
regulation of the epigenome is extensive and can occur
across large domains with wide-ranging impact on the
process of carcinogenesis.
Methods
Tissue culture
HMEC lines (Table 1) were generated from tissue re-
moved from healthy women during breast reduction
mammoplasty with informed consent and approval from
the Sydney Adventist Hospital Human Research Ethics
Committee and prepared according to the protocol set
out in Stampfer et al. [53]. HMEC lines were expanded in
MBD170 serum-free basal medium (Life Technologies,
Carlsbad CA, USA) until proliferation slowed and the cells
entered the selection phase (passage 4 to 7). Selection
phase HMEC were maintained with twice-weekly media
changes until large colonies (1 to 2 cm) of growth were
observed (2 to 4 weeks). Growing cells were trypsinised
Table 1 HMEC donor details
Donor Age Passage
HMEC Early vHMEC Late vHMEC
Bre12 23 3* (3#) 10* (7#) 16* (14#)
Bre38 29 5* (3#) 11* (7#) 14* (26#)
Bre67 23 2* (2#) 7* (7#) 14* (14#)
Bre98 30 2* (2#) 8* (7#) 14* (14#)
*Passage used for expression profiling. #Passage used for methylation
profiling. HMEC, human mammary epithelial cells; vHMEC, variant HMEC.
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and transferred to a new culture vessel, generating the
vHMEC lines. At the time of surgery, all donors were aged
between 23 and 43 years of age.
MBDCap-seq
Methylated DNA Binding Domain protein Capture
followed by sequencing (MBDCap-seq) utilised 1 μg gen-
omic DNA sonicated to mean fragment size of approxi-
mately 500 bp using a Bioruptor® water bath sonicator
(Diagenode, Denville NJ, USA). Methylated DNA was cap-
tured using the Methylminer® Methylated DNA Enrichment
Kit (Life Technologies, Carlsbad CA, USA) according to the
manufacturer’s protocol and total captured DNA was eluted
with one high salt wash (2,000 mM). Sequencing was
performed on 10 ng MBD captured DNA on the Illumina
GAIIX sequencing platform (Illumina, San Diego, CA,
USA) at the Ramaciotti Centre for Gene Function Analysis
(RCGFA) or The Beijing Genomics Institute (BGI) generat-
ing single end 36 bp reads at RCGFA and 50 bp at BGI.
Short sequence reads from Illumina sequencing were
mapped to the human genome build HG18 with Bowtie
[54]. Reads mapping to multiple locations, containing se-
quencing errors or duplicated reads were discarded from
further analysis. The number of reads mapping at any
given locus depends upon CpG density [55]. Therefore, to
identify all genomic loci assayable by MBDCap-seq, an
SssI treated 100% methylated sample (CpGenome Univer-
sally methylated DNA, Merck Millipore, Billerica MA,
USA) was used to identify regions of the genome attract-
ing a sufficient number of reads for the reliable detection
of DNA methylation status. Specifically, the findPeaks
function of the Homer peak-calling suite of programs [56]
was applied to the SssI material (parameter settings of
style = histone, size = 300, minDist = 300, tagThreshold =
18) which identified 230,655 assayable loci covering ap-
proximately 116 Mb across the genome. The edgeR Bio-
conductor package [57-59] was then used to model the
distribution of reads in assayable loci to detect regions
with statistically significant changes in read density.
Clonal bisulphite sequencing
Bisulphite conversion of DNA was performed according
to a previously published protocol [60]. Briefly, genomic
DNA (1 μg) was incubated in cell lysis solution (100 ng/μl
tRNA, 280 ng/μl Proteinase K, 1% SDS) at 37°C for 1 h to
ensure complete protein digestion. NaOH (Sigma-Aldrich,
St Louis, MO, USA) was added to a final concentration
0.3 M and DNA was denatured at 90°C for 5 min, then
rapidly cooled on ice. The denatured sample was com-
bined with a saturated solution of sodium metabisulphite
(pH 5) and 10 mM Quinol (0.5 mM final Quinol concen-
tration) and incubated at 55°C for 16 h. Bisulphite treated
DNA was purified (Wizard® DNA Clean-Up System,
Promega, Madison, WI, USA) according to the manufac-
turer’s protocol and desulphonated by the addition of
NaOH to a final concentration of 0.3 M followed by incu-
bation at 37°C for 15 min then purified by ethanol
precipitation.
PCR amplification of bisulphite converted DNA was
performed using Platinum Taq Polymerase (Life Tech-
nologies) according to the manufacturer’s protocol using
the primers listed in Additional file 2: Table S8 under
nested or fully nested conditions. PCR products were
cloned into the pGEM T-easy cloning kit (Promega) and
sequenced at Australian Cancer Research Foundation
facility, located within the Garvan Institute of Medical
Research, Sydney, Australia.
Taqman low-density miRNA array
High-quality RNA was converted to cDNA using the
Megaplex Pools® for microRNA expression analysis cDNA
synthesis kit (Life Technologies, Carlsbad CA, USA)
according to the manufacturer’s protocol, without pre-
amplification. The total cDNA reaction was loaded onto a
TLDA and qPCR was performed on an AbiPrism 7900HT
(Life Technologies, Carlsbad CA, USA) sequence detec-
tion system. TLDA qPCR data was analysed using the
HTqPCR R package [61] by the ΔΔCt method (normalised
to the included control genes). Genes either lowly or in-
variably expressed across all patients and time points were
excluded, leaving 116 out of 379 miRNA for further ana-
lysis. Predicted miRNA targets were identified using the
microrna.org database [62]. To remove spurious interac-
tions, predictions were limited to those that had a mirSVR
score of < −0.5.
Expression microarray
Gene expression profiling was performed by Affymetrix
GeneChip® Human Gene 1.0 ST arrays (at one time
point in the HMEC growth phase and two time points
in the vHMEC phase referred to as early and late
vHMEC, respectively), Taqman Low-Density miRNA ar-
rays and RNA-seq.
RNA was extracted using TRIzol® reagent (Life Tech-
nologies, Carlsbad CA, USA) according to manufacturer’s
protocol and quality assessed on the Agilent Bioanalyzer
RNA Nano chip (Agilent Technologies, Santa Clara CA,
USA) to ensure an RNA integrity number (RIN) of >9.
RNA labelling and hybridisation to Affymetrix GeneChip®
1.0ST expression arrays was performed at the Ramaciotti
Centre for Gene Function Analysis (UNSW, Sydney,
Australia). Data analysis was performed using aroma.affy-
metrix [63]. Robust Multi-Array (RMA) normalisation to
summarise gene-probe intensities and differentially
expressed genes were identified using limma [64].
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TCGA data acquisition and analysis
Processed RNA-Seq expression data (level 3) and raw
HM450 methylation data (level 1) were obtained from the
TCGA data portal in January 2012 and clinical annotation
from the 2012 TCGA-BRCA cohort primary publication
[65]. Raw methylation data was pre-processed and back-
ground normalised with Bioconductor minfi package
using preprocessIllumina (…, bg.correct = TRUE,
normalize = ‘controls’, reference = 1) command. HM450
probes exhibiting differential methylation were identified
using limma. Comparisons were carried out between all
tumours and normal or basal-like tumours and all normal
samples. For ROC analysis, the database was split
randomly into two cohorts (75% and 25% of all samples,
respectively) to allow training and testing of the models.
ROC was performed using ROCR. For tumour-specific re-
gions, regions exhibiting an AUC of >0.95 in the test co-
hort (after training) were selected as having potential
utility as a diagnostic marker. For basal-like specific
methylation, regions with an AUC of >0.7 were taken as
having potential clinical utility.
ChIP-seq
ChIP was performed according to the manufacturer’s
protocol (17–295, Millipore, Billerica MA, USA). Briefly,
approximately 2 × 106 cells were fixed in culture medium
plus 1% (w/v) formaldehyde for 10 min at 37°C. Fixed
chromatin was sonicated to a mean fragment size of ap-
proximately 500 bp and immunoprecipitation performed
for the chromatin marks H3K4me3, H3K27ac, H3K36me3
and H3K27me3 (see Additional file 2: Table S9 for anti-
body conditions). H3K4me3 profiling was performed on
HMEC and early vHMEC from donors Bre67 and Bre98
and H3K27ac, H3K27me3 and H3K36me3 ChIP-seq was
performed on donor Bre98 only. Illumina 36 bp single end
sequencing was performed on 5 to 12 ng of ChIP DNA at
either the Ramaciotti Centre for Gene Function Analysis
or the Beijing Genomics Institute (see Additional file 2:
Table S10 for sequencing summary statistics).
Short sequence reads from Illumina sequencing were
aligned to the human genome build hg18 with bowtie [54]
and regions of enrichment were identified using the
Homer peak calling algorithm (Settings; H3K4me3: −min-
TagThreshold 10 -size 600 -minDist 600 -F 0 -L 0 -C 0,
H3K27ac: −region -size 2000 -minDist 4000 -localSize
1000000 -F 0 -L 0 -C 0, H3K27me3 & H3K36me3; −re-
gion -fdr 1e-04 -minTagThreshold 40 -size 2000 -minDist
4000 -localSize 1000000 -F 0 -L 0 -C 0) [56]. Large regions
of enrichment were broken into non-overlapping 1,000 bp
tiles for the chromatin marks H3K27ac, H3K36me3 and
H3K27me3 whereas, H3K4me3 exhibited smaller regions
that did not need to be tiled. The density of sequence
reads in regions of enrichment was assessed with edgeR
[57-59] to establish regions of statistically significant
chromatin marking in each time. Where regions had to be
tiled, adjacent statistically significant regions were com-
bined into a single region and an aggregate statistic calcu-
lated using Fisher’s exact test.
ChIP-chip profiling
ChIP-chip profiling for H3K9ac was performed on do-
nors Bre12 and Bre38, and H3K27me3 ChIP-chip was
performed on donors Bre12, Bre38, Bre67 and Bre98.
ChIP and input DNA for array hybridisation was ampli-
fied to ensure sufficient yield prior to fragmentation and la-
belling (recommended 7.5 μg per ChIP-chip experiment).
H3K27me3 ChIP DNA was amplified once with the Geno-
mePlex® Complete Whole Genome Amplification (WGA)
Kit (WGA2, Sigma-Aldrich, St. Louis, MO, USA). WGA2
amplification gave insufficient yield when performed on
H3K9ac ChIP DNA. Therefore, H3K9ac ChIP DNA was
amplified once with WGA2 and reamplified with the
GenomePlex® WGA Reamplification Kit (WGA3, Sigma-
Aldrich, St. Louis, MO, USA).
WGA material was cleaned up with the GeneChip® Sam-
ple Cleanup Module (Affymetrix, Santa Clara, CA, USA)
and 7.5 μg was then fragmented and labelled for array
hybridisation with the GeneChip® WT Double-Stranded
Target Assay (Affymetrix, Santa Clara, CA, USA) according
to the manufacturer’s protocols. Fragmented and labelled
WGA ChIP and input DNA was hybridised to GeneChip®
Human Promoter 1.0R arrays (Affymetrix, Santa Clara, CA,
USA) at the RCGFA. Low level analysis and Model-based
Analysis of Tiling arrays (MAT) normalisation of ChIP-chip
data was performed using aroma.affymetrix [63]. Array sig-
nal across all promoters on the array was determined using
Repitools [55,66,67]. ChIP data was then summarised to a
t-statistic for a region of ±2 kb of all transcription start sites
(TSS) with the function blocksStats [67]. Regions of LRER
were identified by the methods set out in Bert et al. [30].
Availability of supporting data
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super series GSE58882.
Additional files
Additional file 1: Supplementary Figures. Figures S1 to S14 and
associated figure legends.
Additional file 2: Supplementary Tables. Table S1 IPA TF
deregulation predictions. Table S2. Predicted targets of deregulated
miRNA (microrna.org). Table S3. TarBase validated targets of deregulated
miRNA. Table S4. Coordinates and summary of vHMEC LRER. Table S5.
Tumour specific vHMEC DMRs. Table S6. TFBS associated with candidate
diagnostic DMRs. Table S7. Basal-like tumour specific vHMEC DMRs.
Table S8. Bisulphite converted primer sequences, conditions and
coordinates (HG18). Table S9. Antibodies used for ChIP-seq. Table S10.
ChIP-seq validation primer sequences, conditions and coordinates (HG18).
Locke et al. Clinical Epigenetics  (2015) 7:52 Page 13 of 15
Abbreviations
AUC: area under the curve; ChIP: chromatin immunoprecipitation; ChIP-
seq: ChIP followed by next generation sequencing; DMR: differentially
methylated region; GSEA: gene set enrichment analysis; HM450: Infinium
Human Methylation 450 beadchip; HMEC: human mammary epithelial cells;
IPA: Ingenuity Pathway Analysis; LREA: long-range epigenetic activation;
LRER: long-range epigenetic regulation; LRES: long-range epigenetic
silencing; MBDCap-seq: Methylated DNA Binding Domain protein Methylated
DNA Capture followed by next generation sequencing; MDS: multi-
dimensional scaling; ROC: receiver operator characteristics; TCGA: The Cancer
Genome Atlas; TCGA-BRCA: The Cancer Genome Atlas Invasive Breast
Carcinoma Cohort; TF: transcription factor; TFBS: transcription factor binding
site; TLDA: Taqman Low-Density Array; vHMEC: variant human mammary
epithelial cells.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WJL performed all experiments, performed some bioinformatic analysis and
writing of the manuscript. EZ designed and performed the bioinformatic
analysis of MBDCap-seq and ChIP-seq data and MDR performed the analysis
of the gene expression array data. CS and AS contributed to manuscript
preparation. RAH contributed to initial experimentation. RRR and LIH
provided organoids/HMECs and associated protocols. SJC conceived of the
study design and writing of the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
All work was performed using funding from the following grants,
scholarships and fellowships; National Breast Cancer Foundation of Australia
Postgraduate Research Scholarship #DS-09-06 (WJL, http://www.nbcf.org.au/),
National Breast Cancer Foundation of Australia Collaborative Grant entitled
‘Novel strategies for prediction and control of advanced breast cancer via
nanoscaled epigenetic-based biosensors’ (SJL, http://www.nbcf.org.au/),
National Health and Medical Research Council Project grant #1011447 (SJL
https://www.nhmrc.gov.au/), National Health and Medical Research Council
Fellowship #1063559 (SJL https://www.nhmrc.gov.au/), National Health and
Medical Research Council Project Grant #1070881 (LIH, RRR https://
www.nhmrc.gov.au/), New South Wales Cancer Council Program Grant
#PG11-08 (RRR http://www.cancercouncil.com.au/).
Author details
1Epigenetic Research Laboratory, Genomics and Epigenetic Division, The
Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW
2010, Australia. 2St. Vincent’s Clinical School, Faculty of Medicine, University
of New South Wales, Level 5 deLacy Building, St Vincent’s Hospital, Victoria
Street, Darlinghurst, NSW 2010, Australia. 3Swiss Institute of Bioinformatics,
University of Zurich, Zurich, and Institute of Molecular Life Sciences,
University of Zurich, Winterthurerstrasse 190, Zurich CH-8057, Switzerland.
4Sydney West Cancer Trials Centre, Crown Princess Mary Cancer Centre
Westmead, Westmead Hospital, Hawkesbury Road, Westmead, NSW 2145,
Australia. 5Cancer Research Unit, Children’s Medical Research Institute, 2145
Hawkesbury Road, Westmead, NSW 2145, Australia. 6Sydney Medical School,
University of Sydney, Fisher Road, Sydney, NSW 2006, Australia.
Received: 24 November 2014 Accepted: 16 April 2015
References
1. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological
and translational implications. Nat Rev Cancer. 2011;11:726–34.
2. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer.
Science. 2013;339:1567–70.
3. Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R,
et al. Hypomethylation of retrotransposable elements correlates with
genomic instability in non-small cell lung cancer. Int J Cancer.
2009;124:81–7.
4. Narayan A, Ji W, Zhang XY, Marrogi A, Graff JR, Baylin SB, et al.
Hypomethylation of pericentromeric DNA in breast adenocarcinomas.
Int J Cancer. 1998;77:833–8.
5. Prada D, Gonzalez R, Sanchez L, Castro C, Fabian E, Herrera LA. Satellite 2
demethylation induced by 5-azacytidine is associated with missegregation
of chromosomes 1 and 16 in human somatic cells. Mutat Res.
2012;729:100–5.
6. Jackson M, Krassowska A, Gilbert N, Chevassut T, Forrester L, Ansell J, et al.
Severe global DNA hypomethylation blocks differentiation and induces
histone hyperacetylation in embryonic stem cells. Mol Cell Biol.
2004;24:8862–71.
7. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene
expression patterns of breast carcinomas distinguish tumor subclasses with
clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.
8. Easwaran H, Johnstone SE, Van Neste L, Ohm J, Mosbruger T, Wang Q, et al.
A DNA hypermethylation module for the stem/progenitor cell signature of
cancer. Genome Res. 2012;22:837–49.
9. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, Olsson H, et al.
Molecular subtypes of breast cancer are associated with characteristic DNA
methylation patterns. Breast Cancer Res. 2010;12:R36.
10. Locke WJ, Clark SJ. Epigenome remodelling in breast cancer: insights from
an early in vitro model of carcinogenesis. Breast Cancer Res. 2012;14:215.
11. Stone A, Cowley MJ, Valdes-Mora F, McCloy RA, Sergio CM, Gallego-Ortega
D, et al. BCL-2 hypermethylation is a potential biomarker of sensitivity to
antimitotic chemotherapy in endocrine-resistant breast cancer. Mol Cancer
Ther. 2013;12:1874–85.
12. Stone A, Valdes-Mora F, Gee JM, Farrow L, McClelland RA, Fiegl H, et al.
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in
anti-hormone resistant breast cancer. PLoS One. 2012;7, e40466.
13. Hinshelwood RA, Clark SJ. Breast cancer epigenetics: normal human
mammary epithelial cells as a model system. J Mol Med. 2008;86:1315–28.
14. Hammond SL, Ham RG, Stampfer MR. Serum-free growth of human mammary
epithelial cells: rapid clonal growth in defined medium and extended serial
passage with pituitary extract. Proc Natl Acad Sci U S A. 1984;81:5435–9.
15. Huschtscha LI, Noble JR, Neumann AA, Moy EL, Barry P, Melki JR, et al. Loss
of p16INK4 expression by methylation is associated with lifespan extension
of human mammary epithelial cells. Cancer Res. 1998;58:3508–12.
16. Tlsty TD, Crawford YG, Holst CR, Fordyce CA, Zhang J, McDermott K, et al.
Genetic and epigenetic changes in mammary epithelial cells may mimic
early events in carcinogenesis. J Mammary Gland Biol Neoplasia.
2004;9:263–74.
17. Brenner AJ, Stampfer MR, Aldaz CM. Increased p16 expression with first
senescence arrest in human mammary epithelial cells and extended growth
capacity with p16 inactivation. Oncogene. 1998;17:199–205.
18. Foster SA, Wong DJ, Barrett MT, Galloway DA. Inactivation of p16 in human
mammary epithelial cells by CpG island methylation. Mol Cell Biol.
1998;18:1793–801.
19. Novak P, Jensen TJ, Garbe JC, Stampfer MR, Futscher BW. Stepwise DNA
methylation changes are linked to escape from defined proliferation barriers
and mammary epithelial cell immortalization. Cancer Res. 2009;69:5251–8.
20. Hinshelwood RA, Huschtscha LI, Melki J, Stirzaker C, Abdipranoto A, Vissel B,
et al. Concordant epigenetic silencing of transforming growth factor-beta
signaling pathway genes occurs early in breast carcinogenesis. Cancer Res.
2007;67:11517–27.
21. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
J Clin Oncol. 2009;27:1160–7.
22. Sorlie T, Borgan E, Myhre S, Vollan HK, Russnes H, Zhao X, et al. The
importance of gene-centring microarray data. Lancet Oncol. 2010;11:719–20.
author reply 720–711.
23. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-
expression profiles to predict distant metastasis of lymph-node-negative
primary breast cancer. Lancet. 2005;365:671–9.
24. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An
expression signature for p53 status in human breast cancer predicts
mutation status, transcriptional effects, and patient survival. Proc Natl
Acad Sci U S A. 2005;102:13550–5.
25. Tian Y, Ke S, Chen M, Sheng T. Interactions between the aryl hydrocarbon
receptor and P-TEFb. Sequential recruitment of transcription factors and
differential phosphorylation of C-terminal domain of RNA polymerase II at
cyp1a1 promoter. J Biol Chem. 2003;278:44041–8.
26. Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, et al. A Myc network
accounts for similarities between embryonic stem and cancer cell
transcription programs. Cell. 2010;143:313–24.
Locke et al. Clinical Epigenetics  (2015) 7:52 Page 14 of 15
27. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org
resource: targets and expression. Nucleic Acids Res. 2008;36:D149–153.
28. Vergoulis T, Vlachos IS, Alexiou P, Georgakilas G, Maragkakis M, Reczko M,
et al. TarBase 6.0: capturing the exponential growth of miRNA targets with
experimental support. Nucleic Acids Res. 2012;40:D222–229.
29. Coolen MW, Stirzaker C, Song JZ, Statham AL, Kassir Z, Moreno CS, et al.
Consolidation of the cancer genome into domains of repressive chromatin
by long-range epigenetic silencing (LRES) reduces transcriptional plasticity.
Nat Cell Biol. 2010;12:235–46.
30. Bert SA, Robinson MD, Strbenac D, Statham AL, Song JZ, Hulf T, et al. Regional
activation of the cancer genome by long-range epigenetic remodeling. Cancer
Cell. 2013;23:9–22.
31. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The
human genome browser at UCSC. Genome Res. 2002;12:996–1006.
32. Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, Wong M, et al. The
UCSC genome browser database: extensions and updates 2013. Nucleic
Acids Res. 2013;41:D64–69.
33. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P,
Mesirov JP. Molecular signatures database (MSigDB) 3.0. Biogeosciences.
2011;27:1739–40.
34. Dumont N, Crawford YG, Sigaroudinia M, Nagrani SS, Wilson MB, Buehring
GC, et al. Human mammary cancer progression model recapitulates
methylation events associated with breast premalignancy. Breast Cancer
Res. 2009;11:R87.
35. Wang C, Xu CX, Bu Y, Bottum KM, Tischkau SA. Beta-naphthoflavone
(DB06732) mediates estrogen receptor-positive breast cancer cell cycle
arrest through AhR-dependent regulation of PI3K/AKT and MAPK/ERK
signaling. Carcinogenesis. 2014;35:703–13.
36. Saito R, Miki Y, Hata S, Takagi K, Iida S, Oba Y, et al. Aryl hydrocarbon
receptor in breast cancer-a newly defined prognostic marker. Hormones
Cancer. 2014;5:11–21.
37. Prigent L, Robineau M, Jouneau S, Morzadec C, Louarn L, Vernhet L, Fardel
O, Sparfel L: The aryl hydrocarbon receptor is functionally upregulated early
in the course of human T-cell activation. European J Immunol 2014.
38. O’Donnell EF, Koch DC, Bisson WH, Jang HS, Kolluri SK. The aryl
hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen
receptor-negative hepatoma and breast cancer cells. Cell Death Disease.
2014;5:e1038.
39. Wang K, Li Y, Jiang YZ, Dai CF, Patankar MS, Song JS, et al. An endogenous
aryl hydrocarbon receptor ligand inhibits proliferation and migration of
human ovarian cancer cells. Cancer Lett. 2013;340(1):63–71.
40. Hayashi S, Okabe-Kado J, Honma Y, Kawajiri K. Expression of Ah receptor
(TCDD receptor) during human monocytic differentiation. Carcinogenesis.
1995;16:1403–9.
41. Papoutsis AJ, Selmin OI, Borg JL, Romagnolo DF. Gestational exposure to the
AhR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin induces BRCA-1 promoter
hypermethylation and reduces BRCA-1 expression in mammary tissue of rat
offspring: Preventive effects of resveratrol. Molecul Carcinogenesis.
2013;54(4):261–9.
42. Frauenstein K, Sydlik U, Tigges J, Majora M, Wiek C, Hanenberg H, et al.
Evidence for a novel anti-apoptotic pathway in human keratinocytes
involving the aryl hydrocarbon receptor, E2F1, and checkpoint kinase 1.
Cell Death Differ. 2013;20(10):63–71.
43. Papoutsis AJ, Borg JL, Selmin OI, Romagnolo DF. BRCA-1 promoter
hypermethylation and silencing induced by the aromatic hydrocarbon
receptor-ligand TCDD are prevented by resveratrol in MCF-7 cells.
J Nutr Biochem. 2012;23:1324–32.
44. Ray SS, Swanson HI. Dioxin-induced immortalization of normal human
keratinocytes and silencing of p53 and p16INK4a. J Biol Chem.
2004;279:27187–93.
45. Huschtscha LI, Moore JD, Noble JR, Campbell HG, Royds JA, Braithwaite AW,
et al. Normal human mammary epithelial cells proliferate rapidly in the
presence of elevated levels of the tumor suppressors p53 and p21
(WAF1/CIP1). J Cell Sci. 2009;122:2989–95.
46. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, et al. miR-145
participates with TP53 in a death-promoting regulatory loop and targets
estrogen receptor-alpha in human breast cancer cells. Cell Death Differ.
2010;17:246–54.
47. Kornegoor R, Moelans CB, Verschuur-Maes AH, Hogenes MC, de Bruin PC,
Oudejans JJ, et al. Promoter hypermethylation in male breast cancer:
analysis by multiplex ligation-dependent probe amplification. Breast Cancer
Res. 2012;14:R101.
48. Moelans CB, Verschuur-Maes AH, van Diest PJ. Frequent promoter
hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal
carcinoma in situ and invasive breast cancer. J Pathol. 2011;225:222–31.
49. Vidal LJ, Perry JK, Vouyovitch CM, Pandey V, Brunet-Dunand SE, Mertani HC,
et al. PAX5alpha enhances the epithelial behavior of human mammary
carcinoma cells. Mol Cancer Res. 2010;8:444–56.
50. Pei L, Choi JH, Liu J, Lee EJ, McCarthy B, Wilson JM, et al. Genome-wide
DNA methylation analysis reveals novel epigenetic changes in chronic
lymphocytic leukemia. Epigenetics. 2012;7:567–78.
51. van Roon EH, Boot A, Dihal AA, Ernst RF, van Wezel T, Morreau H, et al.
BRAF mutation-specific promoter methylation of FOX genes in colorectal
cancer. Clin Epigenet. 2013;5:2.
52. Vincent A, Omura N, Hong SM, Jaffe A, Eshleman J, Goggins M. Genome-
wide analysis of promoter methylation associated with gene expression
profile in pancreatic adenocarcinoma. Clin Cancer Res. 2011;17:4341–54.
53. Stampfer M. Isolation and growth of human mammary epithelial cells.
J Tissue Cult Methods. 1985;9:107–15.
54. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient
alignment of short DNA sequences to the human genome. Genome Biol.
2009;10:R25.
55. Robinson MD, Stirzaker C, Statham AL, Coolen MW, Song JZ, Nair SS, et al.
Evaluation of affinity-based genome-wide DNA methylation data: effects of
CpG density, amplification bias, and copy number variation. Genome Res.
2010;20:1719–29.
56. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple
combinations of lineage-determining transcription factors prime cis-
regulatory elements required for macrophage and B cell identities.
Mol Cell. 2010;38:576–89.
57. Robinson MD, Smyth GK. Small-sample estimation of negative binomial
dispersion, with applications to SAGE data. Biostatistics. 2008;9:321–32.
58. Robinson MD, Smyth GK. Moderated statistical tests for assessing differences
in tag abundance. Bioinformatics. 2007;23:2881–7.
59. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for
differential expression analysis of digital gene expression data.
Bioinformatics. 2010;26:139–40.
60. Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M. DNA methylation:
bisulphite modification and analysis. Nat Protoc. 2006;1:2353–64.
61. Dvinge H, Bertone P. HTqPCR: high-throughput analysis and visualization of
quantitative real-time PCR data in R. Bioinformatics. 2009;25:3325–6.
62. Betel D, Koppal A, Agius P, Sander C, Leslie C. Comprehensive modeling of
microRNA targets predicts functional non-conserved and non-canonical
sites. Genome Biol. 2010;11:R90.
63. Bengtsson H, Simpson K, Bullard J, Hansen K: Aroma.affymetrix: a generic
framework in R for analyzing small to very large Affymetrix data sets in
bounded memory. Tech Report #745, Department of Statistics, University of
California, Berkeley, February 2008.
64. Smyth G: limma: linear models for microarray data bioinformatics and
computational biology solutions using R and bioconductor. In. Edited by
Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S: Springer New York;
2005: 397–420: Statistics for Biology and Health].
65. Cancer Genome Atlas N: Comprehensive molecular portraits of human
breast tumours. Nature 2012, 490:61–70.
66. Robinson MD, Statham AL, Speed TP, Clark SJ. Protocol matters: which
methylome are you actually studying? Epigenomics. 2010;2:587–98.
67. Statham AL, Strbenac D, Coolen MW, Stirzaker C, Clark SJ, Robinson MD.
Repitools: an R package for the analysis of enrichment-based epigenomic
data. Bioinformatics. 2010;26:1662–3.
Locke et al. Clinical Epigenetics  (2015) 7:52 Page 15 of 15
